| 1 | Kallmann syndrome | Enrichment | ANOS1, CHD7, FGF8, FGFR1, PROK2, PROKR2, SOX10 | 10.55 |
| 2 | Normosmic congenital hypogonadotropic hypogonadism | Enrichment | CHD7, FGF8, FGFR1, PROK2, PROKR2 | 10.24 |
| 3 | Hypogonadotropic hypogonadism 1 with or without anosmia | Enrichment | ANOS1, PROKR2, SOX10 | 7.50 |
| 4 | Hypogonadotropic hypogonadism | Enrichment | ANOS1, FGFR1, PROKR2 | 6.57 |
| 5 | Septooptic dysplasia | Enrichment | FGFR1, OTX2, PROKR2 | 6.16 |
| 6 | Hypogonadotropic hypogonadism 7 with or without anosmia | Enrichment | ANOS1, FGFR1, PROKR2 | 5.94 |
| 7 | Male infertility with spermatogenesis disorder | Enrichment | CHD7, PROK2, PROKR2 | 5.84 |
| 8 | Male infertility with azoospermia or oligozoospermia due to single gene mutation | Enrichment | FGF8, PROK2, PROKR2, PTPN11 | 5.83 |
| 9 | Rosette-forming glioneuronal tumor | Enrichment | FGFR1, PIK3CA | 5.64 |
| 10 | Hypogonadotropic hypogonadism 2 with or without anosmia | Enrichment | FGFR1, PROKR2 | 5.16 |
| 11 | Hypogonadotropic hypogonadism 5 with or without anosmia | Enrichment | CHD7, SEMA3E | 5.16 |
| 12 | Holoprosencephaly | Enrichment | FGF8, FGFR1 | 4.64 |
| 13 | Holoprosencephaly 1 | Enrichment | FGF8, FGFR1 | 4.47 |
| 14 | Breast adenocarcinoma | Enrichment | AKT1, PIK3CA | 4.47 |
| 15 | Charge syndrome | Enrichment | CHD7, SEMA3E | 4.09 |
| 16 | Cowden syndrome | Enrichment | AKT1, PIK3CA | 4.09 |
| 17 | Nanophthalmos | Enrichment | OTX2, TMEM98 | 3.90 |
| 18 | Specific learning disability | Enrichment | MAPK1, PTPN11 | 3.90 |
| 19 | Meningioma | Enrichment | AKT1, PIK3CA | 3.83 |
| 20 | Noonan syndrome and noonan-related syndrome | Enrichment | MAP2K2, PTPN11 | 3.63 |
| 21 | Microform holoprosencephaly | Enrichment | FGF8, FGFR1 | 3.57 |
| 22 | Lobar holoprosencephaly | Enrichment | FGF8, FGFR1 | 3.57 |
| 23 | Semilobar holoprosencephaly | Enrichment | FGF8, FGFR1 | 3.46 |
| 24 | Noonan syndrome 1 | Enrichment | MAP2K2, PTPN11 | 3.25 |
| 25 | Scoliosis | Enrichment | CHD7, PTPN11 | 3.21 |
| 26 | Rasopathy | Enrichment | MAP2K2, PTPN11 | 3.14 |
| 27 | Macrodactyly | Enrichment | PIK3CA | 2.81 |
| 28 | Proteus syndrome | Enrichment | AKT1 | 2.81 |
| 29 | Osteoglophonic dysplasia | Enrichment | FGFR1 | 2.81 |
| 30 | Metachondromatosis | Enrichment | PTPN11 | 2.81 |
| 31 | Trigonocephaly 1 | Enrichment | FGFR1 | 2.81 |
| 32 | Hypogonadotropic hypogonadism 3 with or without anosmia | Enrichment | PROKR2 | 2.81 |
| 33 | Megalencephaly, autosomal dominant | Enrichment | PIK3CA | 2.81 |
| 34 | Leopard syndrome 1 | Enrichment | PTPN11 | 2.81 |
| 35 | Nanophthalmos 4 | Enrichment | TMEM98 | 2.81 |
| 36 | Cowden syndrome 5 | Enrichment | PIK3CA | 2.81 |
| 37 | Hypogonadotropic hypogonadism 23 with or without anosmia | Enrichment | LHB | 2.81 |
| 38 | Cerebral cavernous malformations 4 | Enrichment | PIK3CA | 2.81 |
| 39 | Noonan syndrome 13 | Enrichment | MAPK1 | 2.81 |
| 40 | Nanophthalmos 1 | Enrichment | MYRF | 2.81 |
| 41 | Hypogonadotropic hypogonadism 4 with or without anosmia | Enrichment | PROK2 | 2.81 |
| 42 | Microphthalmia, syndromic 5 | Enrichment | OTX2 | 2.81 |
| 43 | Hemifacial myohyperplasia | Enrichment | PIK3CA | 2.81 |
| 44 | Capillary malformation of the lower lip, lymphatic malformation of face and neck, asymmetry of face and limbs, and partial/generalized overgrowth | Enrichment | PIK3CA | 2.81 |
| 45 | Scoliosis, isolated 3 | Enrichment | CHD7 | 2.81 |
| 46 | Cardiofaciocutaneous syndrome 4 | Enrichment | MAP2K2 | 2.81 |
| 47 | Pituitary hormone deficiency, combined, 6 | Enrichment | OTX2 | 2.81 |
| 48 | Cowden syndrome 6 | Enrichment | AKT1 | 2.81 |
| 49 | Hypogonadotropic hypogonadism 6 with or without anosmia | Enrichment | FGF8 | 2.81 |
| 50 | Hartsfield syndrome | Enrichment | FGFR1 | 2.81 |
| 51 | Cardiac-urogenital syndrome | Enrichment | MYRF | 2.81 |
| 52 | Encephalitis/encephalopathy, mild, with reversible myelin vacuolization | Enrichment | MYRF | 2.81 |
| 53 | Segmental progressive overgrowth syndrome with fibroadipose hyperplasia | Enrichment | PIK3CA | 2.81 |
| 54 | Hypospadias | Enrichment | PIK3CA | 2.81 |
| 55 | Rare venous malformation | Enrichment | PIK3CA | 2.81 |
| 56 | Diaphragmatic eventration | Enrichment | PIK3CA | 2.81 |
| 57 | Pik3ca-related overgrowth spectrum | Enrichment | PIK3CA | 2.81 |
| 58 | Rare combined vascular malformation | Enrichment | PIK3CA | 2.81 |
| 59 | Cavernous lymphangioma | Enrichment | PIK3CA | 2.81 |
| 60 | Pik3ca-related overgrowth syndrome | Enrichment | PIK3CA | 2.81 |
| 61 | Hartsfield-bixler-demyer syndrome | Enrichment | FGFR1 | 2.81 |
| 62 | Hemihyperplasia-multiple lipomatosis syndrome | Enrichment | PIK3CA | 2.81 |
| 63 | Eccrine angiomatous hamartoma | Enrichment | PIK3CA | 2.81 |
| 64 | Macrodactyly of toe | Enrichment | PIK3CA | 2.81 |
| 65 | Chd7 disorder | Enrichment | CHD7 | 2.81 |
| 66 | Malignant astrocytoma | Enrichment | PTPN11 | 2.81 |
| 67 | Hereditary breast carcinoma | Enrichment | AKT1, PIK3CA | 2.68 |
| 68 | Agnathia-otocephaly complex | Enrichment | OTX2 | 2.51 |
| 69 | Waardenburg syndrome, type 4c | Enrichment | SOX10 | 2.51 |
| 70 | Keratosis, seborrheic | Enrichment | PIK3CA | 2.51 |
| 71 | Pfeiffer syndrome | Enrichment | FGFR1 | 2.51 |
| 72 | Jackson-weiss syndrome | Enrichment | FGFR1 | 2.51 |
| 73 | Encephalocraniocutaneous lipomatosis | Enrichment | FGFR1 | 2.51 |
| 74 | Choanal atresia, posterior | Enrichment | CHD7 | 2.51 |
| 75 | Noonan syndrome 8 | Enrichment | PIK3CA | 2.51 |
| 76 | Werner syndrome | Enrichment | PTPN11 | 2.51 |
| 77 | Peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease | Enrichment | SOX10 | 2.51 |
| 78 | Dextrocardia | Enrichment | MYRF | 2.51 |
| 79 | Interfrontal craniofaciosynostosis | Enrichment | FGFR1 | 2.51 |
| 80 | Tafro syndrome | Enrichment | MAP2K2 | 2.51 |
| 81 | Waardenburg syndrome, type 2a | Enrichment | SOX10 | 2.33 |
| 82 | Pompe disease, infantile-onset | Enrichment | PIK3CA | 2.33 |
| 83 | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi | Enrichment | PIK3CA | 2.33 |
| 84 | Chromosome 8p11 myeloproliferative syndrome | Enrichment | FGFR1 | 2.33 |
| 85 | Pyloric stenosis | Enrichment | CHD7 | 2.33 |
| 86 | Butterfly-shaped pigment dystrophy | Enrichment | OTX2 | 2.33 |
| 87 | Tricuspid valve insufficiency | Enrichment | PTPN11 | 2.33 |
| 88 | Keratoacanthoma | Enrichment | PIK3CA | 2.33 |
| 89 | Breast cancer | Enrichment | AKT1, PIK3CA | 2.23 |
| 90 | Cardiofaciocutaneous syndrome 1 | Enrichment | MAP2K2 | 2.21 |
| 91 | Neurofibromatosis-noonan syndrome | Enrichment | MAP2K2 | 2.21 |
| 92 | Megalencephaly-capillary malformation-polymicrogyria syndrome | Enrichment | PIK3CA | 2.21 |
| 93 | Chromosome 22q11.2 deletion syndrome, distal | Enrichment | MAPK1 | 2.21 |
| 94 | Cardiofaciocutaneous syndrome | Enrichment | MAP2K2 | 2.21 |
| 95 | Cerebrovascular disease | Enrichment | PIK3CA | 2.21 |
| 96 | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia | Enrichment | PTPN11 | 2.21 |
| 97 | Noonan syndrome with multiple lentigines | Enrichment | PTPN11 | 2.21 |
| 98 | Familial cerebral cavernous malformations | Enrichment | PIK3CA | 2.21 |
| 99 | Haddad syndrome | Enrichment | ASCL1 | 2.21 |
| 100 | Capillary malformations, congenital | Enrichment | PIK3CA | 2.11 |
| 101 | Martsolf syndrome 1 | Enrichment | ANOS1 | 2.11 |
| 102 | Pseudovaginal perineoscrotal hypospadias | Enrichment | ANOS1 | 2.11 |
| 103 | Lymphoma | Enrichment | PTPN11 | 2.11 |
| 104 | Hemimegalencephaly | Enrichment | PIK3CA | 2.11 |
| 105 | Primary hypereosinophilic syndrome | Enrichment | FGFR1 | 2.11 |
| 106 | Colorectal cancer | Enrichment | AKT1, PIK3CA | 2.10 |
| 107 | Klippel-trenaunay-weber syndrome | Enrichment | PIK3CA | 2.03 |
| 108 | Cowden syndrome 1 | Enrichment | PIK3CA | 2.03 |
| 109 | Hemihyperplasia, isolated | Enrichment | PIK3CA | 2.03 |
| 110 | Waardenburg syndrome, type 4a | Enrichment | SOX10 | 2.03 |
| 111 | Anxiety | Enrichment | OTX2 | 2.03 |
| 112 | Wiedemann-steiner syndrome | Enrichment | CHD7 | 2.03 |
| 113 | 3mc syndrome | Enrichment | CHD7 | 2.03 |
| 114 | Patent ductus arteriosus | Enrichment | PTPN11 | 2.03 |
| 115 | Lung squamous cell carcinoma | Enrichment | PIK3CA | 2.03 |
| 116 | Waardenburg syndrome | Enrichment | SOX10 | 2.03 |
| 117 | Ovarian cancer | Enrichment | AKT1, PIK3CA | 1.98 |
| 118 | Nevus, epidermal | Enrichment | PIK3CA | 1.97 |
| 119 | Waardenburg syndrome, type 1 | Enrichment | SOX10 | 1.97 |
| 120 | Waardenburg syndrome, type 2e | Enrichment | SOX10 | 1.97 |
| 121 | Capillary malformation-arteriovenous malformation 1 | Enrichment | PIK3CA | 1.97 |
| 122 | Noonan syndrome 3 | Enrichment | PTPN11 | 1.97 |
| 123 | Gallbladder cancer | Enrichment | PIK3CA | 1.97 |
| 124 | Pilomyxoid astrocytoma | Enrichment | FGFR1 | 1.97 |
| 125 | Hypothyroidism | Enrichment | CHD7 | 1.91 |
| 126 | Difference of sex development | Enrichment | MYRF | 1.91 |
| 127 | Combined pituitary hormone deficiency | Enrichment | OTX2 | 1.91 |
| 128 | Arteriovenous malformation | Enrichment | PIK3CA | 1.86 |
| 129 | Adult hepatocellular carcinoma | Enrichment | PIK3CA | 1.86 |
| 130 | Microcephaly | Enrichment | MAPK1, PTPN11 | 1.82 |
| 131 | Cat eye syndrome | Enrichment | CHD7 | 1.81 |
| 132 | Omenn syndrome | Enrichment | CHD7 | 1.81 |
| 133 | Myopathy, x-linked, with excessive autophagy | Enrichment | PIK3CA | 1.81 |
| 134 | Pectus excavatum | Enrichment | PTPN11 | 1.77 |
| 135 | Atrial heart septal defect | Enrichment | CHD7 | 1.77 |
| 136 | Lung non-small cell carcinoma | Enrichment | PIK3CA | 1.77 |
| 137 | Interatrial communication | Enrichment | CHD7 | 1.77 |
| 138 | Epicanthus | Enrichment | PTPN11 | 1.73 |
| 139 | Juvenile myelomonocytic leukemia | Enrichment | PTPN11 | 1.73 |
| 140 | Lip and oral cavity carcinoma | Enrichment | PIK3CA | 1.73 |
| 141 | Congenital long qt syndrome | Enrichment | PTPN11 | 1.73 |
| 142 | Diaphragmatic hernia, congenital | Enrichment | MYRF | 1.70 |
| 143 | Heart disease | Enrichment | CHD7 | 1.67 |
| 144 | Pituitary stalk interruption syndrome | Enrichment | PROKR2 | 1.67 |
| 145 | 46,xy partial gonadal dysgenesis | Enrichment | OTX2 | 1.67 |
| 146 | Myopia | Enrichment | CHD7 | 1.64 |
| 147 | Lynch syndrome | Enrichment | PIK3CA | 1.64 |
| 148 | Septopreoptic holoprosencephaly | Enrichment | FGF8 | 1.64 |
| 149 | Midline interhemispheric variant of holoprosencephaly | Enrichment | FGF8 | 1.64 |
| 150 | Gliosarcoma | Enrichment | FGFR1 | 1.61 |
| 151 | Giant cell glioblastoma | Enrichment | FGFR1 | 1.58 |
| 152 | Alobar holoprosencephaly | Enrichment | FGF8 | 1.58 |
| 153 | Heart, malformation of | Enrichment | MAPK1 | 1.56 |
| 154 | Patent foramen ovale | Enrichment | PTPN11 | 1.56 |
| 155 | Macs syndrome | Enrichment | OTX2 | 1.52 |
| 156 | Cardiomyopathy, dilated, 1a | Enrichment | SEMA3E | 1.49 |
| 157 | Endometrial cancer | Enrichment | PIK3CA | 1.49 |
| 158 | Hepatocellular carcinoma | Enrichment | PIK3CA | 1.47 |
| 159 | Microphthalmia | Enrichment | OTX2 | 1.47 |
| 160 | Tooth agenesis | Enrichment | FGFR1 | 1.47 |
| 161 | Hydrops fetalis, nonimmune | Enrichment | PTPN11 | 1.40 |
| 162 | Strabismus | Enrichment | PTPN11 | 1.39 |
| 163 | Bladder cancer | Enrichment | PIK3CA | 1.36 |
| 164 | Hirschsprung disease 1 | Enrichment | SOX10 | 1.36 |
| 165 | Prostate cancer | Enrichment | PIK3CA | 1.36 |
| 166 | Long qt syndrome 1 | Enrichment | PTPN11 | 1.34 |
| 167 | Non-immune hydrops fetalis | Enrichment | PTPN11 | 1.33 |
| 168 | Lung cancer | Enrichment | PIK3CA | 1.31 |
| 169 | Gastric cancer | Enrichment | PIK3CA | 1.19 |
| 170 | Hypertrophic cardiomyopathy | Enrichment | PTPN11 | 1.19 |
| 171 | Thrombocytopenia | Enrichment | PTPN11 | 1.14 |
| 172 | Hypertelorism | Enrichment | PIK3CA | 1.11 |
| 173 | Rare genetic deafness | Enrichment | SOX10 | 0.94 |
| 174 | Leber plus disease | Enrichment | OTX2 | 0.86 |
| 175 | Autism spectrum disorder | Enrichment | PTPN11 | 0.81 |
| 176 | Inherited cancer-predisposing syndrome | Enrichment | PTPN11 | 0.73 |